Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC
Description:
There were an estimated 19,880 new cases of ovarian cancer last year
in the United States, and an estimated 12,810 deaths due to ovarian
cancer in the US, according to the American Cancer Society. Ovarian
cancer is usually found late, stage 3 or higher, where it has
already spread or metastasized to other parts of the abdomen, or
worse. This is due in large part to a lack of symptoms during the
earlier stages. The five year survival rate is only 45%. Fortunately
for patients with ovarian cancer, the treatment paradigm has
exploded in the past three years, giving medical directors and
clinicians more options in managing patients with ovarian cancer.
Leading the way in new options for ovarian cancer are poly
(ADP-ribose) polymerase (PARP) inhibitors, which have shown improved
efficacy for patients with ovarian cancer. Additionally, new
indications for these targeted agents offer expanded options in the
maintenance setting in varying lines of therapy. It is important for
medical directors, oncologists, and nurses who manage ovarian cancer
patient populations to have a solid understanding of the mechanistic
rationale for the use of these medications in order to optimize
their therapeutic application.
Upon completion of this
activity, participants will be able to:
-
Review the clinical and economic
burden of ovarian cancer in terms of relative survival,
mortality, drug utilization, adverse event management, and
hospitalizations
-
Assess the role of germline and
somatic genetic, genomic, and other biomarker testing that is
necessary to inform treatment decision-making in ovarian cancer
-
Evaluate current and emerging data
on PARP inhibitors, including during first-line maintenance, as
single agents or in combination therapies for ovarian cancer
-
Identify patients with advanced
ovarian cancer for whom a PARP inhibitor is an appropriate
choice for the next step in the management of their cancer
-
Compare and contrast adverse events
associated with PARP inhibitors in the management of ovarian
cancer in order to maximize tolerability and adherence to
therapeutic regimens
-
Identify strategies to promote
optimal and equitable clinical integration of PARP inhibitors
for patients with ovarian cancer to reduce associated costs,
minimize healthcare disparities, and improve outcomes for
patients
Faculty:
Richard T. Penson, MD, MRCP
Clinical Director, Medical Gynecologic Oncology
Associate Professor, Harvard Medical School
IRB Chair, Dana Farber Harvard Cancer Center
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Penson has served on an advisory board for Aadi Bioscience,
AstraZeneca, GlaxoSmithKline, ImmunoGen, Merck, Mersana, Novacure,
Roche Pharma, Sutro Biopharma, and Vascular Biogenics. He has
received grant/research support from Array BioPharma, AstraZeneca,
Eisai, Genentech, and Vascular Biogenics. All relevant conflicts of
interest have been mitigated..
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by educational grants from
AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme LLC
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |